Stereotactic ablative radiotherapy-driven immunosuppression is associated with poorer progression-free survival in cancer patients
These findings support a role for lymphocytes in preventing disease progression after SABR and suggest that a change to clinical practice to spare lymphocytes from the toxic effects of irradiation may have beneficial effects for patients.
Authors
- C. Pembroke
- Andrew Godkin
- Arissa Young (ORCID: https://orcid.org/0000-0002-0612-0498)
- Thomas Rackley
- Awen Gallimore
- Owen Nicholas (ORCID: https://orcid.org/0000-0002-6099-2107)
- Stefan Milutinovic (ORCID: https://orcid.org/0000-0002-3163-3383)
- Ashley Poon-King
- Hannah Reed
- Lorenzo Capitani (ORCID: https://orcid.org/0000-0003-1232-569X)
- Jessica L. Oliver (ORCID: https://orcid.org/0000-0002-3464-0247)
- M. Kuczyński
Institutions
- Swansea Bay University Health Board (GB)
- Velindre Cancer Centre (GB)
- Cardiff University (GB)
Publication Details
- Journal
- Cancer Immunology Immunotherapy
- Published
- 2025-12-18
- DOI
- https://doi.org/10.1007/s00262-025-04218-6
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Cancer Research UK
- Medical Research Council